⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVTX News
Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63 rd European Renal Association (ERA) 2026 Congress
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
businesswire.com
TVTX
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI ® (sparsentan) in IgA Nephropathy
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Form 8-K
sec.gov
TVTX
Travere Therapeutics to Participate at Upcoming Investor Conferences
businesswire.com
TVTX